Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alnylam Pharmaceuticals
(NQ:
ALNY
)
250.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
September 08, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
September 08, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
August 04, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Why Is Alnylam (ALNY) Stock Up 50% Today?
August 03, 2022
ALNY stock is quickly moving higher as Wall Street weighs Alnylam's encouraging results for a hard-to-treat condition.
Via
InvestorPlace
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
August 29, 2022
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
August 29, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
August 24, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
August 18, 2022
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart?
August 17, 2022
If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today
August 12, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 9.06% on an annualized basis producing an average annual return of 16.5%. Currently, Alnylam...
Via
Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug
August 05, 2022
The company will compete with Pfizer, which already has an approved drug.
Via
Investor's Business Daily
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
August 04, 2022
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients.
Via
Investor's Business Daily
Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed
August 04, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) brought in sales totaling $224.82 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 15.42%, resulting in a loss of $277.40...
Via
Benzinga
Moderna, PayPal And Some Other Big Gainers From Wednesday
August 04, 2022
U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 03, 2022
Via
Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
August 03, 2022
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
What Is Going on With Helius Medical (HSDT) Stock Today?
August 03, 2022
Helius Medical (HSDT) stock is rocketing higher on Wednesday despite a lack of news from the medical device holding company.
Via
InvestorPlace
Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics
August 03, 2022
Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why
August 03, 2022
Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study.
Via
Investor's Business Daily
Why Alnylam Pharma Shares Are Trading Higher During Premarket Session
August 03, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 03, 2022
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.